Ra Capital Management, L.P. Krystal Biotech, Inc. Transaction History

Ra Capital Management, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 14, 2018	SELL	$8.99 - $15.26 $4.46 Million - $7.57 Million	-496,071 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$8.61 - $11.74 $1.76 Million - $2.39 Million	-203,929 Reduced 29.13%	496,071 $5.01 Million
Q3 2017 Nov 14, 2017	BUY	$9.75 - $10.64 $6.83 Million - $7.45 Million	700,000	700,000 $6.98 Million

310

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.89B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Ra Capital Management, L.P. with notifications on news.